Table 3.
Subgroup analysis on blood lipid biomarkers: stratification by participants’ characteristics.
| Factor Subgroups | TAG (mmol/L) DM (95% CI) 1 |
TC (mmol/L) DM (95% CI) 1 |
LDL (mmol/L) DM (95% CI) 1 |
HDL (mmol/L) DM (95% CI) 1 |
|---|---|---|---|---|
| Age | ||||
| ≥40 | −0.11 (−0.35, 0.13) | −0.03 (−0.41, 0.36) | −0.08 (−0.38, 0.22) | 0.05 (−0.10, 0.19) |
| Mixed | −0.11 (−0.19, −0.02) * | −0.10 (−0.19, −0.00) | −0.09 (−0.18, −0.00) * | 0.04 (0.01, 0.08) * |
| Sex | ||||
| F | −0.14 (−0.40, 0.11) | −0.22 (−0.53, 0.09) | −0.12 (−0.41, −0.17) | 0.04 (−0.06, 0.14) |
| M | −0.10 (−0.42, 0.22) | −0.03 (−0.45, 0.39) | −0.07 (−0.41, 0.26) | 0.07 (−0.10, 0.23) |
| Mixed | −0.10 (−0.19, −0.02) * | −0.08 (−0.19, 0.02) | −0.09 (−0.18, 0.01) | 0.04 (0.01, 0.08) * |
| Country | ||||
| Asia | −0.17 (−0.32, −0.03) * | −0.24 (−0.43,−0.06) ** | −0.27 (−0.45,−0.09) ** | 0.05 (−0.01, 0.11) |
| EU/N. America | −0.08 (−0.17, 0.01) | −0.04 (−0.15, 0.07) | −0.04 (−0.13, 0.06) | 0.04 (−0.00, 0.09) |
| BMI | ||||
| Normal | −0.06 (−0.16, 0.00) | −0.05 (−0.18, 0.08) | −0.02 (−0.13, 0.09) | 0.04 (−0.01, 0.09) |
| Overweight | −0.20 (−0.40, 0.01) | −0.07 (−0.31, 0.16) | −0.08 (−0.29, 0.13) | 0.03 (−0.61, 0.12) |
| Mixed | −0.14 (−0.27, −0.00) * | −0.23 (−0.40, −0.05) * | −0.28 (−0.46, −0.10) ** | 0.07 (0.01, 0.14) * |
| Disease | ||||
| With disease | −0.20 (−0.43, 0.04) | −0.13 (−0.33, 0.07) | −0.20 (−0.38, −0.02) * | 0.06 (−0.01, 0.12) |
| No disease | −0.08 (−0.17, 0.00) | −0.08 (−0.20, 0.02) | −0.05 (−0.15, 0.05) | 0.05 (0.00, 0.09) * |
| Baseline levels | ||||
| Normal | −0.21 (−0.43, 0.02) | −0.08 (−0.19, 0.04) | −0.08 (−0.18, 0.01) | 0.04 (−0.01, 0.09) |
| Dyslipidemia | −0.09 (−0.18, −0.01) * | −0.10 (−0.32, 0.12) | −0.1 (−0.30, 0.08) | 0.05 (0.00, 0.10) * |
1 Significance levels: ** for p value ≤ 0.01, * for p value ≤ 0.05. See Supplementary Materials Table S2 for complete data (DM, 95% CI, p value, I2 and p value for Q test).